Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8Significant progress with collaborators including selection of lead candidate by Janssen Biotech and IND clearance for SGN-EGFRd2 (LAVA-1223) by SeagenPortfolio reprioritization and extension of cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody
Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVAStrong balance sheet expected to provide cash runway into 2026 UTRECHT, The. | June 8, 2023